Currently Recruiting
11 drug trials actively seeking PKD patients. Links go directly to ClinicalTrials.gov enrollment pages.
How to enroll in a clinical trial
Click the "View on ClinicalTrials.gov" link for any trial below to see eligibility criteria, locations, and contact information. Always discuss participation with your nephrologist first.
Drug Trials Enrolling Patients (11)
Click "View on ClinicalTrials.gov" for eligibility criteria, locations, and contact information
Undisclosed mechanism; IV infusion every 4 weeks for 92 weeks
Human monoclonal antibody against PAPPA
ACLY inhibitor / AMPK activator
SGLT2 inhibitor
Undisclosed oral drug candidate developed for ADPKD.
Thiazide diuretic added to tolvaptan
Oral small molecule
AMPK activator
Peptide-oligonucleotide conjugate that blocks the miR-17 binding site on PKD1 mRNA, restoring polycystin-1 (PC1) production while leaving miR-17's other targets untouched. Delivered IV.
Dopamine D5 receptor agonist (transdermal patch)
GLP-1/GIP dual receptor agonist
Disclaimer: Enrollment links direct to ClinicalTrials.gov, where you can find full eligibility criteria and site locations. Meeting eligibility criteria does not guarantee enrollment. Always consult your nephrologist before participating in a clinical trial.